Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
1.
Biomolecules ; 11(9)2021 09 09.
Article in English | MEDLINE | ID: mdl-34572548

ABSTRACT

Bone metastasis is a serious and often lethal complication of particularly frequent carcinomas, such as breast and prostate cancers, which not only reduces survival but also worsens the patients' quality of life. Therefore, it is important to find new and/or additional therapeutic possibilities that can counteract the colonization of bone tissue. High adherence to the Mediterranean diet (MD) is effective in the prevention of cancer and improves cancer patients' health, thus, here, we considered its impact on bone metastasis. We highlighted some molecular events relevant for the development of a metastatic phenotype in cancer cells and the alterations of physiological bone remodeling, which occur during skeleton colonization. We then considered those natural compounds present in MD foods with a recognized role to inhibit or reverse the metastatic process both in in vivo and in vitro systems, and we reported the identified mechanisms of action. The knowledge of this bioactivity by the dietary components of the MD, together with its wide access to all people, could help not only to maintain healthy status but also to improve the quality of life of patients with bone metastases.


Subject(s)
Bone Neoplasms/secondary , Breast Neoplasms/therapy , Chemotherapy, Adjuvant , Diet, Mediterranean , Disease Progression , Food , Prostatic Neoplasms/therapy , Breast Neoplasms/pathology , Female , Humans , Male , Prostatic Neoplasms/pathology
2.
Biomedicines ; 8(8)2020 Aug 03.
Article in English | MEDLINE | ID: mdl-32756375

ABSTRACT

We have previously described the role played by toxic-metal burdens in the etiology of neurodegenerative diseases (ND). We herein report an updated evaluation of toxic-metal burdens in human subjects affected or not affected by ND or other chronic diseases. Each subject underwent a chelation test with the chelating agent calcium disodium ethylenediaminetetraacetic acid (CaNA2EDTA or EDTA) to identify the presence of 20 toxic metals in urine samples using inductively coupled plasma mass spectrometry. Our results show the constant presence of toxic metals, such as lead, cadmium, cesium, and aluminum, in all examined subjects but the absence of beryllium and tellurium. Gadolinium was detected in patients undergoing diagnostic magnetic resonance imaging. The presence of toxic metals was always significantly more elevated in ND patients than in healthy controls. Treatment with EDTA chelation therapy removes toxic-metal burdens and improves patient symptoms.

3.
Int J Mol Sci ; 20(5)2019 02 26.
Article in English | MEDLINE | ID: mdl-30813622

ABSTRACT

Neurotoxicity can be caused by numerous direct agents, of which toxic metals, organophosphorus pesticides, air pollution, radiation and electromagnetic fields, neurotoxins, chemotherapeutic and anesthetic drugs, and pathogens are the most important. Other indirect causes of neurotoxicity are cytokine and/or reactive oxygen species production and adoptive immunotherapy. The development of neurodegenerative diseases has been associated with neurotoxicity. Which arms are useful to prevent or eliminate neurotoxicity? The chelating agent calcium disodium ethylenediaminetetraacetic acid (EDTA)-previously used to treat cardiovascular diseases-is known to be useful for the treatment of neurodegenerative diseases. This review describes how EDTA functions as a therapeutic agent for these diseases. Some case studies are reported to confirm our findings.


Subject(s)
Chelation Therapy , Edetic Acid/therapeutic use , Neurotoxicity Syndromes/drug therapy , Animals , Humans , Treatment Outcome
4.
Hepat Med ; 8: 105-113, 2016.
Article in English | MEDLINE | ID: mdl-27843363

ABSTRACT

Hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), represents the most frequent complication in patients in early phase following hematopoietic stem-cell transplantation (HSCT). In its severe form, VOD/SOS can be associated with multiorgan failure and with a mortality rate >80% by day +100. Defibrotide (DF) (a mixture of 90% single-stranded phosphodiester oligonucleotides and 10% double-stranded phosphodiester oligonucleotides derived from controlled depolarization of porcine intestinal mucosal DNA) has been proposed for the treatment of SOS due to its ability to restore thrombo-fibrinolytic balance and protect endothelial cells. The present review highlights why the mechanisms of action of DF allow its successful use in the prevention and treatment of SOS following HSCT.

5.
J Inorg Biochem ; 152: 214-8, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26404567

ABSTRACT

There is a distinct correlation between aluminium (Al) intoxication and neurodegenerative diseases (ND). We demonstrated how patients affected by ND showing Al intoxication benefit from short-term treatment with calcium disodium ethylene diamine tetraacetic acid (EDTA) (chelation therapy). Such therapy further improved through daily treatment with the antioxidant Cellfood. In the present study we examined the efficacy of long-term treatment, using both EDTA and Cellfood. Slow intravenous treatment with the chelating agent EDTA (2 g/10 mL diluted in 500 mL physiological saline administered in 2 h) (chelation test) removed Al, which was detected (using inductively coupled plasma mass spectrometry) in urine samples collected from patients over 12 h. Patients that revealed Al intoxication (expressed in µg per g creatinine) underwent EDTA chelation therapy once a week for ten weeks, then once every two weeks for a further six or twelve months. At the end of treatment (a total of 22 or 34 chelation therapies, respectively), associated with daily assumption of Cellfood, Al levels in the urine samples were analysed. In addition, the following blood parameters were determined: homocysteine, vitamin B12, and folate, as well as the oxidative status e.g. reactive oxygen species (ROS), total antioxidant capacity (TAC), oxidized LDL (oxLDL), and glutathione. Our results showed that Al intoxication reduced significantly following EDTA and Cellfood treatment, and clinical symptoms improved. After treatment, ROS, oxLDL, and homocysteine decreased significantly, whereas vitamin B12, folate and TAC improved significantly. In conclusion, our data show the efficacy of chelation therapy associated with Cellfood in subjects affected by Al intoxication who have developed ND.


Subject(s)
Aluminum/poisoning , Chelation Therapy/adverse effects , Neurotoxicity Syndromes/drug therapy , Adolescent , Adult , Aged , Aluminum/blood , Aluminum/urine , Amino Acids/adverse effects , Amino Acids/therapeutic use , Enzyme Therapy , Enzymes/adverse effects , Female , Humans , Male , Middle Aged , Minerals/adverse effects , Minerals/therapeutic use , Neurotoxicity Syndromes/etiology , Sulfates/adverse effects , Sulfates/therapeutic use
6.
Biomed Res Int ; 2014: 758323, 2014.
Article in English | MEDLINE | ID: mdl-25243176

ABSTRACT

The aetiology of neurodegenerative diseases (ND) seems to involve susceptibility genes and environmental factors. Toxic metals are considered major environmental pollutants. Following our study of a case of multiple sclerosis (MS) improvement due to removal of aluminium (Al) and other toxic metals, we have examined the possible relationship between Al intoxication and ND. We used the slow intravenous treatment with the chelating agent EDTA (calcium disodium ethylene diamine tetraacetic acid) (chelation test) to remove Al and detected it in the urine collected from the patients for 12 hours. Patients affected by MS represented 85.6% of total ND. Al was present in 44.8% of cases comprehensive of ND and healthy patients. Al levels were significantly higher in ND patients than in healthy subjects. We here show that treatment of patients affected by Al burden with ten EDTA chelation therapies (EDTA intravenous administration once a week) was able to significantly reduce Al intoxication.


Subject(s)
Aluminum/toxicity , Aluminum/urine , Chelating Agents/therapeutic use , Chelation Therapy/methods , Multiple Sclerosis/drug therapy , Neurodegenerative Diseases/drug therapy , Adolescent , Adult , Aged , Aluminum/isolation & purification , Cohort Studies , Female , Humans , Male , Middle Aged , Neurotoxins/isolation & purification , Neurotoxins/toxicity , Neurotoxins/urine , Treatment Outcome , Young Adult
7.
Biomed Res Int ; 2014: 281510, 2014.
Article in English | MEDLINE | ID: mdl-25114898

ABSTRACT

OBJECTIVE: This prospective pilot study aimed at evaluating the effects of therapy with antioxidant compounds (Cellfood, and other antioxidants) on patients affected by neurodegenerative diseases (ND), who displayed toxic metal burden and were subjected to chelation treatment with the chelating agent calcium disodium ethylenediaminetetraacetic acid (CaNa2EDTA or EDTA). METHODS: Two groups of subjects were studied: (a) 39 patients affected by ND and (b) 11 subjects unaffected by ND (controls). The following blood parameters were analyzed before and after three months' treatment with chelation+Cellfood or chelation+other antioxidants: oxidative status (reactive oxygen species, ROS; total antioxidant capacity, TAC; oxidized LDL, oxLDL; glutathione), homocysteine, vitamin B12, and folate. RESULTS: After 3-months' chelation+Cellfood administration oxLDL decreased, ROS levels were significantly lower, and TAC and glutathione levels were significantly higher than after chelation+other antioxidants treatment, both in ND patients and in controls. Moreover, homocysteine metabolism had also improved in both groups. CONCLUSIONS: Chelation+Cellfood treatment was more efficient than chelation+other antioxidants improving oxidative status and homocysteine metabolism significantly in ND patients and controls. Although limited to a small number of cases, this study showed how helpful antioxidant treatment with Cellfood was in improving the subjects' metabolic conditions.


Subject(s)
Amino Acids/pharmacology , Antioxidants/analysis , Chelating Agents/therapeutic use , Enzymes/pharmacology , Minerals/pharmacology , Neurodegenerative Diseases , Sulfates/pharmacology , Amino Acids/administration & dosage , Antioxidants/metabolism , Cholesterol/blood , Enzymes/administration & dosage , Glutathione/blood , Humans , Lipoproteins/blood , Minerals/administration & dosage , Neurodegenerative Diseases/blood , Neurodegenerative Diseases/drug therapy , Neurodegenerative Diseases/metabolism , Pilot Projects , Prospective Studies , Reactive Oxygen Species/blood , Sulfates/administration & dosage
8.
Biometals ; 25(3): 569-76, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22438029

ABSTRACT

Multiple sclerosis (MS) is a chronic progressive disease of the central nervous system (CNS) provoking disability and neurological symptoms. The exact causes of SM are unknown, even if it is characterized by focal inflammatory lesions in CNS accompanied by autoimmune reaction against myelin. Indeed, many drugs able to modulate the immune response of patients have been used to treat MS. More recently, toxic metals have been proposed as possible causes of neurodegenerative diseases. The objective of this study is to investigate in vivo the impact of heavy metal intoxication in MS progression. We studied the case of a patient affected by MS, who has been unsuccessfully treated for some years with current therapies. We examined his levels of toxic heavy metals in the urine, following intravenous "challenge" with the chelating agent calcium disodium ethylene diamine tetraacetic acid (EDTA).The patient displayed elevated levels of aluminium, lead and mercury in the urine. Indeed, he was subjected to treatment with EDTA twice a month. Under treatment, the patient revealed in time improved symptoms suggestive of MS remission. The clinical data correlated with the reduction of heavy metal levels in the urine to normal range values. Our case report suggests that levels of toxic metals can be tested in patients affected by neurodegenerative diseases as MS.


Subject(s)
Chelating Agents/therapeutic use , Metals, Heavy/metabolism , Multiple Sclerosis/drug therapy , Multiple Sclerosis/metabolism , Adult , Edetic Acid , Humans , Male , Young Adult
9.
BMC Nephrol ; 12: 61, 2011 Nov 14.
Article in English | MEDLINE | ID: mdl-22081953

ABSTRACT

BACKGROUND: Ozonated autohemotherapy (OA) has been previously successfully used in the treatment of patients affected by peripheral occlusive arterial disease. OA consists of an intrafemoral reinfusion of autologous blood previously exposed to a mixture of oxygen/ozone (O2/O3). This study analyzes the effects of OA in protecting rat kidney from ischemia and ischemia/reperfusion damage. METHODS: We performed OA 30 min before the induction of 60 min renal ischemia or at the induction of 60 min postischemic reperfusion in rats subjected to unilateral nephrectomy. In addition, to evidence the possible protection induced by O2/O3 on endothelial functions, the present study analyzes the in vitro effects of O2/O3 on oxygen consumption by human umbilical vein endothelial cells (HUVEC). RESULTS: 1) OA preserves rat kidney functions and architecture, as demonstrated by the improved levels of serum creatinine and blood urea nitrogen and by histology; 2) such protection does not correlate with the increase of plasmatic nitric oxide, but is compatible with a focal renal increase of renal ßNADPH-diaphorase; 3) treatment of HUVEC with O2/O3 significantly increases both the rate of oxygen consumption and the mitochondrial activity assessed by confocal microscopy. CONCLUSION: The preservation of the mitochondrial activity of endothelium could in vivo limit the endothelial dysfunction provoked by the Isc or Isc/R processes.


Subject(s)
Blood Transfusion, Autologous/methods , Kidney/blood supply , Kidney/physiopathology , Nephrectomy/adverse effects , Ozone/administration & dosage , Reperfusion Injury/prevention & control , Reperfusion Injury/physiopathology , Animals , Infusions, Intra-Arterial , Kidney/drug effects , Male , Rats , Rats, Wistar , Reperfusion Injury/etiology , Treatment Outcome
10.
Nutr J ; 10: 77, 2011 Jul 25.
Article in English | MEDLINE | ID: mdl-21781350

ABSTRACT

BACKGROUND: Micronutrient inadequate intake is responsible of pathological deficiencies and there is a need of assessing the effectiveness of metal supplementation, frequently proposed to rebalance poor diets. Manganese (Mn) is present in many enzymatic intracellular systems crucial for the regulation of cell metabolism, and is contained in commercially available metal supplements. METHODS: We compared the effects of two different commercial Mn forms, gluconate (MnGluc) and oxyprolinate (MnOxP). For this purpose we used the polarized Caco-2 cells cultured on transwell filters, an established in vitro model of intestinal epithelium. Since micronutrient deficiency may accelerate mitochondrial efficiency, the mitochondrial response of these cells, in the presence of MnGluc and MnOxP, by microscopy methods and by ATP luminescence assay was used. RESULTS: In the presence of both MnOxP and MnGluc a sustained mitochondrial activity was shown by mitoTraker labeling (indicative of mitochondrial respiration), but ATP intracellular content remained comparable to untreated cells only in the presence of MnOxP. In addition MnOxP transiently up-regulated the antioxidant enzyme Mn superoxide dismutase more efficiently than MnGluc. Both metal treatments preserved NADH and ßNADPH diaphorase oxidative activity, avoided mitochondrial dysfunction, as assessed by the absence of a sustained phosphoERK activation, and were able to maintain cell viability. CONCLUSIONS: Collectively, our data indicate that MnOxP and MnGluc, and primarily the former, produce a moderate and safe modification of Caco-2 cell metabolism, by activating positive enzymatic mechanisms, thus could contribute to long-term maintenance of cell homeostasis.


Subject(s)
Gluconates/pharmacokinetics , Manganese/pharmacokinetics , Biological Availability , Caco-2 Cells , Diet , Humans , Intestinal Mucosa/cytology , Micronutrients/deficiency , Microscopy, Confocal , Mitochondria/metabolism
11.
Biometals ; 24(6): 1093-8, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21655943

ABSTRACT

Toxic metals are involved in the pathogenesis of some neurodegenerative and vascular diseases and are known to impair the immune system functions. We report here the case of a patient affected by heavy metal intoxication, who had developed an autoimmune disease. There was evidence of aluminium, cadmium and lead intoxication in a 63-year old Italian woman affected by rheumatoid arthritis (RA). We treated the patient with calcium disodium edetate (EDTA) once a week for a year in order to remove traces of heavy metal intoxication. Oxidative status profile was carried out at the beginning and after 6 months' EDTA chelation. At the end of the treatment, the patient did not show any signs of metal intoxication, RA symptoms and oxidative status improved.


Subject(s)
Arthritis, Rheumatoid/chemically induced , Arthritis, Rheumatoid/drug therapy , Chelating Agents/therapeutic use , Chelation Therapy/methods , Edetic Acid/therapeutic use , Metals, Heavy/toxicity , Arthritis, Rheumatoid/pathology , Chelating Agents/chemistry , Disease Management , Edetic Acid/chemistry , Female , Humans , Metals, Heavy/chemistry , Metals, Heavy/urine , Middle Aged , Oxidative Stress
12.
Cases J ; 2: 199, 2009 Nov 18.
Article in English | MEDLINE | ID: mdl-19946446

ABSTRACT

INTRODUCTION: A great deal of data regarding the toxicology of mercury has been recently reported. Although the most common human exposures to mercury are currently mercury vapour from amalgam tooth fillings, methylmercury from seafood and ethylmercury as a preservative in vaccines, in the past mercury compounds have been used in the treatment of syphilis. CASE PRESENTATION: Mercury intoxication was found in a 67 year-old Italian man affected by neurological symptoms of apparently unknown origin. The patient developed syphilis forty years ago and then underwent therapy with mercurials to treat his chronic bacterial infection. We treated the patient with disodium edetate chelation therapy. Six months after the beginning of the therapy, the patient's neurological symptoms began to decrease, and were completely cured after two years of therapy. CONCLUSION: This case supports the use of chelation therapy with disodium edetate to remove damages caused by mercury intoxication.

13.
Arch Phys Med Rehabil ; 90(6): 913-8, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19480865

ABSTRACT

OBJECTIVE: To examine the rationale of the combined use of a new expiratory device in association with a previously assessed inspiratory device in improving 3 indicators of the respiratory muscle strength, for example, maximal inspiratory pressure (MIP), maximal expiratory pressure (MEP), and dyspnea grade. DESIGN: Randomized trial. SETTING: Home-based pulmonary rehabilitation. PARTICIPANTS: Adults (N=32; mean age, 68y). MAIN OUTCOME MEASURE: We instructed 32 patients with mild to very severe COPD to use the devices, and randomized them in a 1:1 ratio: they were assigned to the sham training control group (16 patients who trained at a load not able to improve MIP and MEP) or to the training group (16 patients). The patients trained at home twice daily for 15 minutes, 7 days a week, for 12 months. MIP and MEP as well as dyspnea perception were evaluated at 1, 6, and 12 months from the beginning of the training. The impact of additional work of breathing was measured at baseline and after the use of the expiratory device. RESULTS: The patients who performed the respiratory training showed significant and progressive improvements of MIP (81+/-4 at 12 months vs 57+/-7 as basal values expressed in cm H2O; P<.05) and MEP (97+/-2 at 12 months vs 62+/-4 as basal values; P<.05) at the end of the training. In addition, they showed a significant reduction of dyspnea perception (1.18+/-0.29 vs 2.93+/-0.32 as basal values; P<.05) at the end of the training. CONCLUSIONS: This study suggests that home exercise with the combined use of our expiratory and inspiratory devices leads to a significant improvement of respiratory muscle function in patients with mild to very severe COPD.


Subject(s)
Breathing Exercises , Exhalation , Inhalation , Pulmonary Disease, Chronic Obstructive/rehabilitation , Respiratory Muscles/physiopathology , Aged , Equipment and Supplies , Female , Humans , Male , Pulmonary Disease, Chronic Obstructive/physiopathology , Respiratory Function Tests
14.
FASEB J ; 21(12): 3052-62, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17566084

ABSTRACT

UNLABELLED: A growing body of evidence suggests that chromogranin A (CgA), a secretory protein released by many neuroendocrine cells and frequently used as a diagnostic and prognostic serum marker for a range of neuroendocrine tumors, is a precursor of several bioactive fragments. This work was undertaken to assess whether the N-terminal fragment CgA(1-76) (called vasostatin I) can inhibit the proangiogenic activity of vascular endothelial growth factor (VEGF), a factor involved in tumor growth. The effect of recombinant human vasostatin I (VS-1) on VEGF-induced human umbilical endothelial cells (HUVEC) signaling, proliferation, migration, and organization has been investigated. We have found that VS-1 (3 microg/ml; 330 nM) can inhibit VEGF-induced ERK phosphorylation, as well as cell migration, proliferation, morphogenesis, and invasion of collagen gels in various in vitro assays. In addition, VS-1 could inhibit the formation of capillary-like structures in Matrigel plugs in a rat model. VS-1 could also inhibit basal ERK phosphorylation and motility of HUVEC, leading to a more quiescent state in the absence of VEGF, without inducing apoptotic or necrotic effects. CONCLUSION: These findings suggest that vasostatin I may play a novel role as a regulator of endothelial cell function and homeostasis.


Subject(s)
Cell Movement , Cell Proliferation , Chromogranin A/metabolism , Endothelial Cells/physiology , Peptide Fragments/metabolism , Vascular Endothelial Growth Factor A/metabolism , Animals , Cell Culture Techniques , Cell Line , Cell Shape , Chromogranin A/genetics , Collagen , Drug Combinations , Endothelial Cells/cytology , Extracellular Signal-Regulated MAP Kinases/metabolism , Homeostasis , Humans , Laminin , Peptide Fragments/genetics , Phosphorylation , Platelet Endothelial Cell Adhesion Molecule-1/metabolism , Proteoglycans , Rats , Rats, Inbred F344 , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , von Willebrand Factor/metabolism
15.
Respirology ; 11(6): 799-804, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17052311

ABSTRACT

OBJECTIVE AND BACKGROUND: The benefits of inspiratory muscle strength training in decreasing symptoms, disability or handicap of patients affected by COPD are not well established. The objective of this study was to assess the efficacy of the constant use of a new flow-volumetric inspiratory exerciser, named Respivol, in improving respiratory functional parameters in COPD patients. METHODS: Twenty consecutive ambulatory patients affected by COPD were enrolled. Each patient was assessed, before and after 3 and 6 months inspiratory exercise with Respivol, for the following clinical parameters: maximal inspiratory pressure, maximal expiratory pressure, dyspnoea grade, quality of life by a self-administered St George questionnaire and a 6-min walking test. After a brief progressive ambulatory training programme, inspiratory exercise with Respivol was performed at home for 6 months. All patients used Respivol together with medical treatment. RESULTS: Maximal inspiratory pressure and maximal expiratory pressure values were significantly increased after 3 and 6 months of exercise. Dyspnoea grade was significantly reduced and the 6-min walking test showed an increase in effort tolerance, after 6 months of home training. Quality of life assessment showed an improvement, associated with a decrease of respiratory disease symptoms. CONCLUSIONS: Inspiratory muscle strength training with Respivol seems to be efficient in reducing symptoms and improving quality of life in adults with COPD.


Subject(s)
Equipment and Supplies , Home Care Services , Pulmonary Disease, Chronic Obstructive/rehabilitation , Respiratory Muscles/physiopathology , Respiratory Therapy/methods , Aged , Dyspnea/physiopathology , Dyspnea/rehabilitation , Female , Humans , Inhalation/physiology , Lung/physiopathology , Male , Maximal Expiratory Flow Rate , Middle Aged , Muscle Strength , Physical Endurance/physiology , Quality of Life , Respiratory Function Tests , Walking/physiology
16.
BMC Nephrol ; 7: 5, 2006 Mar 15.
Article in English | MEDLINE | ID: mdl-16536881

ABSTRACT

BACKGROUND: Chelation therapy with sodium edetate (EDTA) improved renal function and slowed the progression of renal insufficiency in patients subjected to lead intoxication. This study was performed to identify the underlying mechanism of the ability of EDTA treatment to protect kidneys from damage. METHODS: The effects of EDTA administration were studied in a rat model of acute renal failure induced by 60 minutes ischemia followed or not by 60 minutes reperfusion. Renal ischemic damage was evaluated by histological studies and by functional studies, namely serum creatinine and blood urea nitrogen levels. Treatment with EDTA was performed 30 minutes before the induction of ischemia. Polymorphonuclear cell (PMN) adhesion capability, plasmatic nitric oxide (NO) levels and endothelial NO synthase (eNOS) renal expression were studied as well as the EDTA protection from the TNFalpha-induced vascular leakage in the kidneys. Data was compared by two-way analysis of variance followed by a post hoc test. RESULTS: EDTA administration resulted in the preservation of both functional and histological parameters of rat kidneys. PMN obtained from peripheral blood of EDTA-treated ischemized rats, displayed a significant reduction in the expression of the adhesion molecule Mac-1 with respect to controls. NO was significantly increased by EDTA administration and eNOS expression was higher and more diffuse in kidneys of rats treated with EDTA than in the controls. Finally, EDTA administration was able to prevent in vivo the TNFalpha-induced vascular leakage in the kidneys. CONCLUSION: This data provides evidence that EDTA treatment is able to protect rat kidneys from ischemic damage possibly through the stimulation of NO production.


Subject(s)
Chelating Agents/pharmacology , Edetic Acid/pharmacology , Ischemia/prevention & control , Kidney/blood supply , Kidney/drug effects , Acute Kidney Injury/drug therapy , Acute Kidney Injury/physiopathology , Acute Kidney Injury/prevention & control , Animals , Blood Urea Nitrogen , Capillary Permeability/drug effects , Capillary Permeability/physiology , Cell Adhesion/physiology , Chelating Agents/therapeutic use , Creatinine/blood , Disease Models, Animal , Disease Progression , Edetic Acid/therapeutic use , Hemodynamics/drug effects , Hemodynamics/physiology , Ischemia/drug therapy , Ischemia/physiopathology , Kidney/chemistry , Kidney/pathology , Macrophage-1 Antigen/analysis , Male , Neutrophils/chemistry , Neutrophils/pathology , Nitric Oxide/metabolism , Nitric Oxide Synthase Type III/analysis , Rats , Rats, Sprague-Dawley , Reperfusion Injury/drug therapy , Reperfusion Injury/physiopathology , Reperfusion Injury/prevention & control , Tumor Necrosis Factor-alpha/pharmacology
17.
BMC Immunol ; 6: 18, 2005 Jul 22.
Article in English | MEDLINE | ID: mdl-16042776

ABSTRACT

BACKGROUND: We previously showed that local use of periodate oxidized ATP (oATP, a selective inhibitor of P2X7 receptors for ATP) in rat paw treated with Freund's adjuvant induced a significant reduction of hyperalgesia Herein we investigate the role of oATP, in the rat paws inflamed by carrageenan, which mimics acute inflammation in humans. RESULTS: Local, oral or intravenous administration of a single dose of oATP significantly reduced thermal hyperalgesia in hind paws of rats for 24 hours, and such effect was greater than that induced by diclofenac or indomethacin. Following oATP treatment, the expression of the pro-inflammatory chemokines interferon-gamma-inducible protein-10 (IP-10), mon ocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8) within the inflamed tissues markedly decreased on vessels and infiltrated cells. In parallel, the immunohistochemical findings showed an impairment, with respect to the untreated rats, in P2X7 expression, mainly on nerves and vessels close to the site of inflammation. Finally, oATP treatment significantly reduced the presence of infiltrating inflammatory macrophages in the paw tissue. CONCLUSION: Taken together these results clearly show that oATP reduces carrageenan-induced inflammation in rats.


Subject(s)
Adenosine Triphosphate/analogs & derivatives , Analgesics, Non-Narcotic/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Chemokines/biosynthesis , Hyperalgesia/drug therapy , Adenosine Triphosphate/administration & dosage , Adenosine Triphosphate/pharmacology , Adenosine Triphosphate/physiology , Adenosine Triphosphate/therapeutic use , Administration, Cutaneous , Administration, Oral , Analgesics, Non-Narcotic/administration & dosage , Analgesics, Non-Narcotic/pharmacology , Animals , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Carrageenan/toxicity , Chemokine CCL2/biosynthesis , Chemokine CCL2/genetics , Chemokine CXCL10 , Chemokines/genetics , Chemokines, CXC/biosynthesis , Chemokines, CXC/genetics , Diclofenac/administration & dosage , Diclofenac/therapeutic use , Disease Models, Animal , Hindlimb , Hot Temperature , Hyperalgesia/chemically induced , Hyperalgesia/etiology , Indomethacin/administration & dosage , Indomethacin/therapeutic use , Injections, Intravenous , Interleukin-8/biosynthesis , Interleukin-8/genetics , Macrophages/drug effects , Male , Purinergic P2 Receptor Antagonists , Rats , Rats, Wistar , Receptors, Purinergic P2/biosynthesis , Receptors, Purinergic P2/genetics , Receptors, Purinergic P2X7 , Single-Blind Method
18.
Nucl Med Biol ; 31(5): 631-8, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15219282

ABSTRACT

We studied the in vivo fate of CD8(+) lymphocytes, of naive (CD8(+)CD45RC(bright)) or memory (CD8(+)CD45RC(dim)) phenotype, injected in syngeneic rats, after their sorting and labeling with [(99m)Tc] HM-PAO. By using the scintigrafic method we showed that memory CD8(+) lymphocytes were able to recirculate into liver and lungs. The same method was also successfully used to in vivo study the homing of total blood lymphocytes obtained from inflamed rats.


Subject(s)
Inflammation/diagnostic imaging , Inflammation/metabolism , Lymphocytes/diagnostic imaging , Technetium Tc 99m Exametazime/pharmacokinetics , Animals , Male , Metabolic Clearance Rate , Organ Specificity , Radionuclide Imaging , Radiopharmaceuticals/pharmacokinetics , Rats , Rats, Inbred F344 , Rats, Inbred Strains , Tissue Distribution
19.
Nucl Med Biol ; 30(6): 633-42, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12900289

ABSTRACT

The knowledge of lymphocyte distribution is very usefulness in monitoring therapeutic treatments. We present here a method employed in clinical practice, the scintigraphy, to study in the rat the physiologic lymphocyte traffic. Rat T cells labeled with 99mTc were injected in syngeneic animals, and their fate was studied by serial scintigraphic scanning. Sorted naïve CD4+ CD45RC(bright) T cells homed to lymphoid organs and accumulated in spleen. CD4+ CD45RC(dim) memory lymphocytes first reached the liver and the lungs and recirculated. The results obtained by using the scintigraphic method to in vivo study the lymphocyte homing in rats are comparable to those obtained with previously used experimental methods. We consider the scintigraphic method a useful tool to in vivo track lymphocytes and to address therapeutic treatment in men.


Subject(s)
CD4 Lymphocyte Count/methods , CD4-Positive T-Lymphocytes/diagnostic imaging , CD4-Positive T-Lymphocytes/physiology , Cell Movement/physiology , Lymphoid Tissue/diagnostic imaging , Technetium Tc 99m Exametazime , Animals , CD4-Positive T-Lymphocytes/immunology , Cell Movement/immunology , Lymphoid Tissue/immunology , Male , Organ Specificity , Radionuclide Imaging , Radiopharmaceuticals , Rats , Rats, Inbred F344 , T-Lymphocytes/diagnostic imaging , T-Lymphocytes/immunology , T-Lymphocytes/physiology
20.
Am J Clin Nutr ; 77(5): 1220-8, 2003 May.
Article in English | MEDLINE | ID: mdl-12716675

ABSTRACT

BACKGROUND: Resveratrol (a naturally occurring phytoalexin found in grapes and wine) has cardiovascular protective effects that suggest the antiatherogenic (ie, antiinflammatory) activities of the compound on endothelial cells. OBJECTIVE: The antiinflammatory activity of resveratrol could be mediated by its interference with nuclear factor-kappaB (NF-kappaB)-dependent transcription. Thus, we studied the in vitro influence of physiologic concentrations of resveratrol (

Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Endothelium, Vascular/metabolism , NF-kappa B/metabolism , Stilbenes/pharmacology , Tumor Necrosis Factor-alpha/pharmacology , Cells, Cultured , Dose-Response Relationship, Drug , Endothelium, Vascular/cytology , Endothelium, Vascular/drug effects , Humans , NF-kappa B p50 Subunit , Phosphorylation/drug effects , Resveratrol , Serine/metabolism , Signal Transduction/drug effects , Transcription Factor RelA , Transcription, Genetic , Tyrosine/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...